HBE-843是一种新的,强大的,有选择性的EGFR向PROTAC,用于治疗非小细胞肺癌
Mohammad Hassan Baig1, Chang Joong Kim1, Nale Sagar Dattatraya1
1BNJ Biopharma, Incheon, Republic of Korea.
Archiv der Pharmazie
|February 4, 2026
概括
一种新的EGFR PROTAC,HBE-843,有效地降解了包括C797S在内的EGFR突变,克服了非小细胞肺癌中针对性治疗的耐药性. 这种有前途的化合物在临床前模型中显示出显著的瘤生长抑制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,EGFR C797S突变赋予了对第三代EGFR-氨酸激酶抑制剂的耐药性.
- 针对突变EGFR,同时保护野生型EGFR对于有效的NSCLC治疗至关重要.
研究的目的:
- 开发和描述一种新的,有选择性的EGFR PROTAC (HBE-843),能够降解突变EGFR,包括C797S耐药性突变.
- 在临床前NSCLC模型中评估HBE-843的疗效和机制.
主要方法:
- 合成和表征HBE-843,一种新的EGFR PROTAC.
- 在体外评估HBE-843对各种EGFR突变 (L858R,外因子19缺失,T790M,C797S) 和野生型EGFR的降解活性.
- 确定GI50,DC50和Dmax值的方法.
- 涉及CRBN相关蛋白酶体通路和ERK信号的机制研究.
- 在L858R诱导的NSCLC异种移植的体内疗效研究.
主要成果:
- HBE-843证明了低纳米GI50值 (26-103 nM) 的EGFR突变 (L858R,外因子19删除,T790M,C797S) 的强烈降解,同时保留了野生型EGFR.
- HBE-843在突变细胞中实现了对EGFR蛋白水平的剂量依赖性降低 (DC50:1.9-18nM,Dmax>90%).
- 降解通过CRBN-蛋白酶体通路发生,抑制ERK信号传递和细胞生长.
- 在体内研究表明,L858R诱导的NSCLC模型中112%的瘤生长抑制.
结论:
- HBE-843是一种高度选择性的EGFR降解剂,对临床相关的EGFR突变具有强烈的活性,包括C797S.
- HBE-843通过蛋白质体降解有效地克服了EGFR突变介导的耐药性.
- HBE-843显示出显著的临床前疗效,并代表了一种有前途的化合物,用于开发NSCLC的新疗法.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
Lung Capacity
56.3K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
T Cell Activation and Clonal Selection
16.1K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.1K
What is Natural Selection?
129.5K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
129.5K
Antibiotic Selection
60.0K
Overview
60.0K


